The 2026 biotech conferences calendar is one of the densest years biopharma and the broader life sciences industry have seen.
FDA approval velocity remains high. Inflation Reduction Act implementation is entering a more consequential phase. Generative AI is moving from R&D experimentation into operational deployment. And biotech investment trends point to a re-opening capital environment after a multi-year reset.
All of that translates into a packed year of events competing for commercial, R&D, investor, and executive attention. [Read more…]




